Alkermes plc logo ALKS - Alkermes plc

Price: -- -- | CONSENSUS: Buy DETAILS
STRONG
BUY 0
BUY 16
HOLD 10
SELL 3
STRONG
SELL 0
| PRICE TARGET: $58.29 DETAILS
HIGH: $65.00
LOW: $50.00
MEDIAN: $56.00
CONSENSUS: $58.29
UPSIDE: 41.41%

Stock News

Alkermes to Present New Data on Alixorexton and LUMRYZ® (sodium oxybate) at Sleep Europe 2026, Underscoring Leadership in Sleep Medicine Research

Alkermes to Present New Data on Alixorexton and LUMRYZ® (sodium oxybate) at Sleep Europe 2026, Underscoring Leadership in Sleep Medicine Research

DUBLIN--(BUSINESS WIRE)--Alkermes plc (Nasdaq: ALKS) today announced plans to present two oral presentations and six posters from its industry-leading portfolio of sleep medicine research at the European Sleep Research Society's (ESRS) 28th Congress, Sleep Europe 2026, taking place Oct. 20-23, 2026 in Maastricht, the Netherlands. The company will present new data related to LUMRYZ® (sodium oxybate) extended-release oral suspension, now part of Alkermes' sleep portfolio following the acquisition.

Oct 13, 2026 03:00 AM • businesswire.com
Stock Picks From Seeking Alpha's September 2026 New Analysts

Stock Picks From Seeking Alpha's September 2026 New Analysts

Seeking Alpha welcomed 38 new analysts in September 2026. This article showcases their top picks and investment strategies. Highlighted companies include Qualcomm, Teladoc, and NewLake Capital Partners, as well as the ETF TDAQ, each with a detailed investment thesis. We invite you all to engage with our new contributing analysts, explore their diverse investment theses, and consider following up on the highlighted stock ideas.

Oct 07, 2026 05:00 AM • seekingalpha.com
Critical Survey: Alkermes (NASDAQ:ALKS) and uniQure (NASDAQ:QURE)

Critical Survey: Alkermes (NASDAQ:ALKS) and uniQure (NASDAQ:QURE)

Alkermes (NASDAQ: ALKS - Get Free Report) and uniQure (NASDAQ: QURE - Get Free Report) are both healthcare companies, but which is the superior stock? We will compare the two companies based on the strength of their analyst recommendations, risk, dividends, institutional ownership, earnings, profitability and valuation. Earnings and Valuation This table compares Alkermes and uniQure"s gross

Oct 06, 2026 04:14 AM • defenseworld.net
Alkermes: Idiopathic Hypersomnia Could Expand Lumryz Into A Larger Growth And Margin Driver

Alkermes: Idiopathic Hypersomnia Could Expand Lumryz Into A Larger Growth And Margin Driver

Alkermes is positioned for significant growth through LUMRYZ's potential expansion into idiopathic hypersomnia (IH), following positive Phase 3 results. LUMRYZ's IH indication could drive incremental revenue, leveraging existing commercial infrastructure and delivering operating leverage with a limited SG&A increase. ALKS faces a 10% royalty to Jazz Pharmaceuticals on non-narcolepsy LUMRYZ sales post-March 2028, but the opportunity remains financially meaningful.

Sep 26, 2026 04:48 AM • seekingalpha.com
Alkermes Announces Positive Phase 1b Results Demonstrating Clinical Proof-of-Concept for ALKS 7290 in Adults With Attention-Deficit Hyperactivity Disorder (ADHD)

Alkermes Announces Positive Phase 1b Results Demonstrating Clinical Proof-of-Concept for ALKS 7290 in Adults With Attention-Deficit Hyperactivity Disorder (ADHD)

DUBLIN--(BUSINESS WIRE)--Alkermes plc (Nasdaq: ALKS) today announced positive topline results from a phase 1 proof-of-concept study evaluating ALKS 7290, the company's novel, investigational orexin 2 receptor (OX2R) agonist in development for the treatment of attention-deficit hyperactivity disorder (ADHD). The study evaluated the safety and tolerability (primary objective) and pharmacokinetics (PK) and pharmacodynamics (PD) of ALKS 7290 in healthy volunteers (n=88) and in adults with ADHD (n=5.

Sep 21, 2026 03:00 AM • businesswire.com
Alkermes Announces Appointment of Anne C. Whitaker to Board of Directors

Alkermes Announces Appointment of Anne C. Whitaker to Board of Directors

DUBLIN--(BUSINESS WIRE)--Alkermes plc (Nasdaq: ALKS) today announced the appointment of a new independent director, Anne C. Whitaker, to the company's Board of Directors (the Board). Ms. Whitaker is a seasoned biopharmaceutical executive and experienced board director who brings deep commercial and operational expertise, as well as a proven track record of driving growth and transformation across global pharmaceutical and biotechnology organizations. “Anne joins our Board at a defining time for.

Sep 16, 2026 03:00 AM • businesswire.com
Alkermes: A Slow-Burning Buy Prospect On Orexin-Agonist Promise

Alkermes: A Slow-Burning Buy Prospect On Orexin-Agonist Promise

Alkermes plc is upgraded from Hold to Buy, driven by robust revenue growth, pipeline momentum, and strategic positioning in sleep and CNS disorders. Acquisition of Avadel and Lumryz launch propel >20% revenue growth in 2026; adjusted EBITDA guidance is $370–410M despite a GAAP net loss. Alixorexton's strong Phase 2 data in narcolepsy and IH, plus advancing orexin pipeline, underpin multi-billion-dollar long-term revenue potential.

Sep 11, 2026 07:30 AM • seekingalpha.com
Alkermes Announces Launch of 9th Annual Alkermes Pathways Research Awards® Program

Alkermes Announces Launch of 9th Annual Alkermes Pathways Research Awards® Program

DUBLIN--(BUSINESS WIRE)--Alkermes plc (Nasdaq: ALKS) today announced that it will begin accepting applications for its annual Alkermes Pathways Research Awards® program on Friday, Sept. 11, 2026. Now in its ninth year, this competitive grant program is designed to support the next generation of researchers working on the front lines to advance our understanding of diseases in the field of neuroscience. Building on prior award cycles, the program will continue to accept applications related to s.

Sep 10, 2026 03:00 AM • businesswire.com
Financial Review: C4 Therapeutics (NASDAQ:CCCC) and Alkermes (NASDAQ:ALKS)

Financial Review: C4 Therapeutics (NASDAQ:CCCC) and Alkermes (NASDAQ:ALKS)

Alkermes (NASDAQ: ALKS - Get Free Report) and C4 Therapeutics (NASDAQ: CCCC - Get Free Report) are both healthcare companies, but which is the superior business? We will compare the two businesses based on the strength of their dividends, earnings, profitability, valuation, risk, analyst recommendations and institutional ownership. Insider and Institutional Ownership 95.2% of Alkermes shares are

Aug 30, 2026 10:29 PM • defenseworld.net
The Lancet Neurology Publishes Data From Alkermes' Positive Vibrance-1 Phase 2 Study of Alixorexton in Adults With Narcolepsy Type 1

The Lancet Neurology Publishes Data From Alkermes' Positive Vibrance-1 Phase 2 Study of Alixorexton in Adults With Narcolepsy Type 1

DUBLIN--(BUSINESS WIRE)--Alkermes plc (Nasdaq: ALKS) today announced the publication of data from the Vibrance‑1 phase 2 study of alixorexton in adults with narcolepsy type 1 (NT1) in The Lancet Neurology. Alixorexton is a novel, investigational, oral, selective orexin 2 receptor (OX2R) agonist in development for the treatment of NT1, narcolepsy type 2 (NT2) and idiopathic hypersomnia (IH). Based on the positive results demonstrated by alixorexton in the phase 2 Vibrance Studies in NT1 and NT2,.

Aug 24, 2026 02:30 PM • businesswire.com

Price Targets